Hospital
New York Eye & Ear Infirmary
New York Eye & Ear Infirmary was paid $38.92M by Medicaid between Jan 2018 and Dec 2024, across 142 billing codes. Its largest line is 92012, Ophthalmological services: medical examination and evaluation, intermediate, established patient — 24% of everything it billed.
33Billing provider infoNEW YORK EYE & EAR INFIRMARY
NEW YORK CITY, NY 10003
NEW YORK CITY, NY 10003
33aNPI1245251222assigned 07/22/2006
33bProvider typeSpecial Hospital
28Total paid$38.92M
24GClaims348,959
24DCodes billed142
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Special Hospital providers in New York
Rank by total paid#1 of 6
Median peer was paid$182K
This provider vs. median214×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,817 | $203K | |
| 2019 | 26,203 | $2.95M | |
| 2020 | 61,187 | $6.50M | |
| 2021 | 77,527 | $7.91M | |
| 2022 | 68,644 | $7.75M | |
| 2023 | 63,799 | $7.48M | |
| 2024incomplete | 48,782 | $6.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 24% | 94,248 | 71,501 | $9.37M |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 13% | 3,112 | 2,947 | $5.14M |
| 67311 | 10.0% | 1,557 | 1,546 | $3.89M | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 4.5% | 2,248 | 2,235 | $1.73M |
| 92002 | 4.4% | 13,129 | 12,933 | $1.73M | |
| 30140 | 4.1% | 764 | 763 | $1.60M | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 4.0% | 1,028 | 1,027 | $1.56M |
| J0178 | Injection, aflibercept, 1 mg | 3.7% | 2,779 | 1,701 | $1.42M |
| 92250 | 3.2% | 17,140 | 14,900 | $1.23M | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 2.8% | 640 | 639 | $1.09M |
| 67028 | Intravitreal injection of a pharmacologic agent | 1.9% | 5,123 | 4,465 | $726K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.7% | 5,570 | 5,066 | $656K |
130 more codes
| 92060 | 1.7% | 7,488 | $655K | |
| 92083 | 1.5% | 7,463 | $570K | |
| 92134 | 1.4% | 6,849 | $545K | |
| 67113 | 1.3% | 166 | $494K | |
| 92567 | 1.2% | 6,740 | $473K | |
| 42830 | 1.2% | 278 | $456K | |
| 92133 | 1.1% | 4,813 | $420K | |
| 67228 | 1.1% | 649 | $416K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,529 | $306K |
| 92557 | <1% | 4,820 | $293K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,842 | $289K |
| 67314 | <1% | 456 | $241K | |
| 30520 | <1% | 587 | $188K | |
| 92235 | <1% | 1,693 | $184K | |
| 92020 | <1% | 2,299 | $173K | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 752 | $150K |
| 21235 | <1% | 204 | $146K | |
| 95782 | <1% | 181 | $145K | |
| 76512 | <1% | 1,629 | $137K | |
| 92604 | <1% | 1,364 | $125K | |
| J3490 | Unclassified drugs | <1% | 31,644 | $124K |
| 92550 | <1% | 1,679 | $121K | |
| 92136 | <1% | 1,618 | $120K | |
| 95811 | <1% | 172 | $118K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,193 | $112K |
| 92025 | <1% | 1,226 | $112K | |
| 31231 | <1% | 353 | $98K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,650 | $94K |
| 92285 | <1% | 1,223 | $94K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,118 | $93K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,923 | $92K |
| V5020 | Conformity evaluation | <1% | 1,306 | $89K |
| V2632 | Posterior chamber intraocular lens | <1% | 5,392 | $85K |
| 92579 | <1% | 1,062 | $80K | |
| 92015 | Determination of refractive state | <1% | 2,779 | $70K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,914 | $63K |
| 65426 | <1% | 26 | $62K | |
| 88304 | <1% | 1,996 | $59K | |
| 31575 | <1% | 177 | $46K | |
| 92626 | <1% | 652 | $44K | |
| 69210 | <1% | 364 | $41K | |
| 88173 | <1% | 941 | $33K | |
| 92537 | <1% | 226 | $29K | |
| OP370 | <1% | 39 | $28K | |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 3,498 | $27K |
| 92524 | <1% | 231 | $27K | |
| 92582 | <1% | 429 | $25K | |
| V2785 | Processing, preserving and transporting corneal tissue | <1% | 25 | $24K |
| 99201 | <1% | 176 | $23K | |
| 95800 | <1% | 143 | $23K | |
| 31267 | <1% | 24 | $21K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 994 | $21K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 645 | $21K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,374 | $16K |
| 92553 | <1% | 207 | $15K | |
| 92540 | <1% | 279 | $15K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 650 | $13K |
| 81025 | <1% | 2,593 | $13K | |
| 70480 | <1% | 92 | $13K | |
| 70486 | <1% | 98 | $12K | |
| 92593 | <1% | 244 | $11K | |
| 80053 | Comprehensive metabolic panel | <1% | 457 | $11K |
| 92520 | <1% | 113 | $10K | |
| 92556 | <1% | 150 | $9K | |
| 92552 | <1% | 105 | $9K | |
| 92555 | <1% | 139 | $9K | |
| J1097 | Phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml | <1% | 73 | $8K |
| 92622 | <1% | 67 | $7K | |
| 88311 | <1% | 522 | $6K | |
| J3473 | Injection, hyaluronidase, recombinant, 1 usp unit | <1% | 361 | $6K |
| V5010 | Assessment for hearing aid | <1% | 74 | $6K |
| 87070 | <1% | 1,254 | $6K | |
| 97162 | <1% | 39 | $5K | |
| J3471 | Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units) | <1% | 74 | $5K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,182 | $4K |
| 92700 | <1% | 53 | $4K | |
| 92132 | <1% | 47 | $4K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 76 | $4K |
| 87075 | <1% | 766 | $3K | |
| 82947 | <1% | 2,912 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 712 | $3K |
| 92603 | <1% | 26 | $3K | |
| OP272 | <1% | 27 | $2K | |
| 87102 | <1% | 675 | $2K | |
| 92585 | <1% | 17 | $2K | |
| 92652 | <1% | 28 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 15 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 110 | $2K |
| OP710 | <1% | 13 | $2K | |
| 92592 | <1% | 36 | $2K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,487 | $1K |
| 92082 | <1% | 17 | $1K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 3,657 | $1K |
| L8610 | Ocular implant | <1% | 27 | $1K |
| J7315 | Mitomycin, ophthalmic, 0.2 mg | <1% | 14 | $991.98 |
| J2704 | Injection, propofol, 10 mg | <1% | 8,376 | $959.21 |
| 87186 | <1% | 97 | $888.92 | |
| 95992 | <1% | 22 | $772.44 | |
| 92591 | <1% | 13 | $655.98 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 2,624 | $534.42 |
| 76511 | <1% | 13 | $532.99 | |
| 76513 | <1% | 12 | $418.33 | |
| 88172 | <1% | 13 | $372.80 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 599 | $285.19 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,552 | $259.63 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,433 | $167.33 |
| A9270 | Non-covered item or service | <1% | 516 | $165.78 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,907 | $161.81 |
| A4217 | Sterile water/saline, 500 ml | <1% | 124 | $157.62 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,438 | $154.53 |
| OP250 | <1% | 123 | $134.47 | |
| 88313 | <1% | 28 | $128.86 | |
| 92570 | <1% | 57 | $128.68 | |
| C1780 | Lens, intraocular (new technology) | <1% | 38 | $108.47 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,572 | $45.86 |
| 86780 | <1% | 28 | $33.60 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,040 | $32.94 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,365 | $27.58 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 360 | $27.21 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 714 | $24.23 |
| 86592 | <1% | 42 | $18.01 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 493 | $17.66 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 62 | $13.20 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 225 | $1.60 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 78 | $0.68 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 14 | $0.31 |
| 85014 | 0% | 28 | $0.00 | |
| 85049 | 0% | 28 | $0.00 | |
| 99429 | 0% | 57 | $0.00 | |
| 85018 | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTSAI, JAMES (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Southland Hematology Oncology Medical Group, INC | Hemet, CA | $2.69M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.